Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has been given a consensus rating of “Buy” by the seven research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $19.80.

Several equities research analysts have recently issued reports on CATX shares. Oppenheimer lowered their price objective on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective on the stock. Lifesci Capital reiterated an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada decreased their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $15.27 on Thursday. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98. The company has a 50 day moving average price of $12.42.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Sell-side analysts forecast that Perspective Therapeutics will post -1.02 EPS for the current year.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor acquired 10,000 shares of the business’s stock in a transaction on Thursday, June 13th. The stock was bought at an average cost of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now owns 13,757 shares in the company, valued at $160,956.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Perspective Therapeutics news, Director Robert F. Williamson III purchased 5,500 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was acquired at an average cost of $13.80 per share, with a total value of $75,900.00. Following the completion of the acquisition, the director now directly owns 42,379 shares of the company’s stock, valued at approximately $584,830.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Johan M. Spoor purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was acquired at an average cost of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at $160,956.90. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 27,811 shares of company stock valued at $345,547. 3.52% of the stock is currently owned by company insiders.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics during the 1st quarter worth about $15,511,000. Affinity Asset Advisors LLC acquired a new position in shares of Perspective Therapeutics during the 1st quarter worth about $6,069,000. Ally Bridge Group NY LLC acquired a new position in shares of Perspective Therapeutics during the 2nd quarter worth about $3,951,000. Finally, WealthPLAN Partners LLC acquired a new position in shares of Perspective Therapeutics during the 2nd quarter worth about $1,695,000. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.